High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3

Nature Immunology

Volumn 15, Issue 2, 2014, Pages 152-160

  De Nardo, Dominic ^a   Labzin, Larisa I ^a   Kono, Hajime ^b   Seki, Reiko ^b   Schmidt, Susanne V ^a   Beyer, Marc ^a   Xu, Dakang ^c,d   Zimmer, Sebastian ^a   Lahrmann, Catharina ^a   Schildberg, Frank A ^a   Vogelhuber, Johanna ^a   Kraut, Michael ^a   Ulas, Thomas ^a   Kerksiek, Anja ^a   Krebs, Wolfgang ^a   Bode, Niklas ^a   Grebe, Alena ^a   Fitzgerald, Michael L ^e   Hernandez, Nicholas J ^e   Williams, Bryan R G ^c   Knolle, Percy ^f   Kneilling, Manfred ^g   Röcken, Martin ^g   Lütjohann, Dieter ^a   Wright, Samuel D ^h   Schultze, Joachim L ^a,j   Latz, Eicke ^a,i   more..

^a UNIVERSITY OF BONN   (Germany)

^b TEIKYO UNIVERSITY   (Japan)

^c MONASH UNIVERSITY   (Australia)

^d HANGZHOU NORMAL UNIVERSITY   (China)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h CSL LIMITED   (Australia)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ALANINE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPEPTIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; CELLS, CULTURED; CHOLESTEROL; CHROMATIN IMMUNOPRECIPITATION; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SYSTEMS BIOLOGY; TOLL-LIKE RECEPTOR 4;

EID: 84892737895     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2784     Document Type: Article

References (51)

1. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
2. Medzhitov, R. & Horng, T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9, 692-703 (2009).
3. Gilchrist, M. et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441, 173-178 (2006).
4. Hai, T., Wolford, C.C. & Chang, Y.S. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expr. 15, 1-11 (2010).
5. Whitmore, M.M. et al. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J. Immunol. 179, 3622-3630 (2007).
6. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
7. Seneviratne, A.N., Sivagurunathan, B. & Monaco, C. Toll-like receptors and macrophage activation in atherosclerosis. Clin. Chim. Acta 413, 3-14 (2012).
8. Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B. & Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714 (1977).
9. Mineo, C. & Shaul, P.W. Novel biological functions of high-density lipoprotein cholesterol. Circ. Res. 111, 1079-1090 (2012).
10. Schwartz, G.G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
11. Boden, W.E. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
12. Rader, D.J. & Tall, A.R. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18, 1344-1346 (2012).
13. Khera, A.V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
14. Libby, P., Ridker, P.M. & Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
15. Murphy, A.J., Westerterp, M., Yvan-Charvet, L. & Tall, A.R. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim. Biophys. Acta 1821, 513-521 (2012).
16. Norata, G.D., Pirillo, A., Ammirati, E. & Catapano, A.L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220, 11-21 (2012).
17. Barter, P.J. et al. Antiinflammatory properties of HDL. Circ. Res. 95, 764-772 (2004).
18. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
19. Sparwasser, T. et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur. J. Immunol. 27, 1671-1679 (1997).
20. Ulevitch, R.J. & Johnston, A.R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J. Clin. Invest. 62, 1313-1324 (1978).
21. Levine, D.M., Parker, T.S., Donnelly, T.M., Walsh, A. & Rubin, A.L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA 90, 12040-12044 (1993).
22. Wurfel, M.M., Hailman, E. & Wright, S.D. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J. Exp. Med. 181, 1743-1754 (1995).
23. Triantafilou, M., Miyake, K., Golenbock, D.T. & Triantafilou, K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115, 2603-2611 (2002).
24. Zhu, X. et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 51, 3196-3206 (2010).
25. Fulton, D.L. et al. TFCat: the curated catalog of mouse and human transcription factors. Genome Biol. 10, R29 (2009).
26. Horton, J.D. et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027-12032 (2003).
27. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
28. Zimarino, M. et al. Optical coherence tomography accurately identifies intermediate atherosclerotic lesions-an in vivo evaluation in the rabbit carotid artery. Atherosclerosis 193, 94-101 (2007).
29. Carmeliet, P. et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am. J. Pathol. 150, 761-776 (1997).
30. Zimmer, S. et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ. Res. 108, 1358-1366 (2011).
31. Seetharam, D. et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 98, 63-72 (2006).
32. Petoumenos, V., Nickenig, G. & Werner, N. High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J. Cell Mol. Med. 13, 4623-4635 (2009).
33. Speer, T. et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38, 754-768 (2013).
34. Saemann, M.D. et al. The versatility of HDL: a crucial anti-inflammatory regulator. Eur. J. Clin. Invest. 40, 1131-1143 (2010).
35. Michelsen, K.S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA 101, 10679-10684 (2004).
36. Mullick, A.E., Tobias, P.S. & Curtiss, L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149-3156 (2005).
37. Kim, T.W. et al. The critical role of IL-1 receptor-associated kinase 4-mediated NF-kappaB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis. J. Immunol. 186, 2871-2880 (2011).
38. Kleemann, R., Zadelaar, S. & Kooistra, T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79, 360-376 (2008).
39. Gold, E.S. et al. ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol-induced lipid body formation. J. Exp. Med. 209, 807-817 (2012).
40. Yvan-Charvet, L. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328, 1689-1693 (2010).
41. Lerch, P.G., Spycher, M.O. & Doran, J.E. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb. Haemost. 80, 316-320 (1998).
42. Murphy, A.J. et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071-2077 (2008).
43. Lerch, P.G., Fortsch, V., Hodler, G. & Bolli, R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 71, 155-164 (1996).
44. Havel, R.J., Eder, H.A. & Bragdon, J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34, 1345-1353 (1955).
45. Thelen, K.M., Laaksonen, R., Paiva, H., Lehtimaki, T. & Lutjohann, D. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J. Clin. Pharmacol. 46, 812-816 (2006).
46. Crameri, A. et al. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J. 25, 432-443 (2006).
47. Fulton, D.L. et al. TFCat: the curated catalog of mouse and human transcription factors. Genome Biol. 10, R29 (2009).
48. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
49. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
50. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
51. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).